Alzheimer's Disease

Doug Whitney, center, eats breakfast with his family in Manson, Wash., on Nov. 5, 2022. Whitney inherited the same gene mutation that gave Alzheimer’s disease to his mother, brother and generations of other relatives by the unusually young age of 50. Doug is a healthy 73, his mind still sharp. Somehow, he escaped his genetic fate. (AP Photo/Shelby Lum)

Science seeking Alzheimer’s clues from few who escape genetic fate

Researchers could uncover and mimic whatever protects those who escaped fate of their families

First Link® Dementia Helpline can provide you with the support and answeres you need.

sponsored

Stand up against dementia stigma this Alzheimer’s Awareness Month

Jana Schulz of Cranbrook, B.C. – a registered social worker, working as…

Jan 9, 2023

FILE — The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday, Sept. 28, 2022, after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s (AP Photo/Steven Senne, File)

VIDEO: Alzheimer’s drug shows promise in early results of study

Patient decline reduced by 27% in initial study

A new study estimates that 6.3 million Canadians will be diagnosed and living with dementia in the next 30 years (Photo: Alzheimer Society)

Canada could see tripling of people living with dementia in next 30 years: Landmark study

The Alzheimer Society of Canada released a study that predicts triple the number of diagnoses

A new study estimates that 6.3 million Canadians will be diagnosed and living with dementia in the next 30 years (Photo: Alzheimer Society)

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

U.S. approves much-debated Alzheimer’s drug aducanumab panned by experts

Drug from Biogen deemed “reasonably likely” to benefit Alzheimer’s patients

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)